Duality Biologics has initiated a trial ( NCT06554795 ) of an anti-B7H3xPD-L1 BsAb ADC, DB-1419, in the United States, Australia, and China. However, Duality Bio has not yet submitted the IND application in China. In 2023, BioNTech and DualityBio entered into a partnership to globally develop, manufacture, and commercialize two assets, including an ADC (DB-1311/BNT324) targeting B7H3. Duality and BioNTech DB-1419 DB-1419 is a bispecific antibody-drug conjugate targeting B7H3 and PD-L1. It was discovered by Duality Biologics and is still in the preclinical stage according to the pipeline on the official website. In 2022 and 2023, Duality Biologics filed patents (WO2024140846 ) covering anti-B7H3xPD-L1 BsAb ADCs. The patent includes examples of bispecific antibody-drug conjugates comprising the following components: an anti-B7H3 and PD-L1 bispecific antibody or an antigen-binding fragment thereof, a linker unit L, and TOP1 inhibitor, with a drug-to-antibody ratio (DAR) of 4, 6, or 8. D
China Biotech XYZ Shares Updates Related to New Drug Development in China